Recent evidence indicates that basal cerebral conduit vessels dilate with hypercapnia, with a nitric oxide (NO) mechanism explaining one way in which parenchymal cerebral arterioles dilate.
INTRODUCTION
Optimal cerebral blood flow (CBF) is achieved through changes in perfusion pressure (Nagata et al., 2016) and adjustments in cerebrovascular conductance (Aaslid, 1992) . The control of cerebral microvasculature has received considerable attention (Hamel, 2005) , whereas the role of the large conduit cerebral arteries in CBF control and its distribution in conscious humans has only recently gained research focus. Early data obtained in larger animal studies (Mchedlishvili, Mitagvaria, & Ormotsadze, 1973; Yoshida, Meyer, Sakamoto, & Handa, 1966) and literature reviews (Faraci & Heistad, 1990) suggest that large intracranial arteries associated with the circle of Willis are key contributors to total cerebral vascular resistance. Also, evidence using high-field magnetic resonance imaging (MRI) indicate that these vessels constrict with hypocapnia and dilate with hypercapnia (Coverdale, Lalande, Perrotta, & Shoemaker, 2015; Kellawan et al., 2016; Verbree et al., 2014) . Therefore, large vessels contribute
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. (Nagata et al., 2016) . Therefore, these vessels are the most studied with respect to cerebrovascular reactivity.
In young and healthy states, hypercapnia elicits an increase in CBF through complex mechanisms that include endothelial (Faraci & Heistad, 1998; Furchgott & Vanhoutte, 1989) and extravascular changes in pH (Kontos, Raper, & Patterson, 1977) and neuronal contributions to the vascular contractile state (Ainslie & Duffin, 2009; Toda, 1983) . Of these mechanisms, nitric oxide (NO) represents a key endothelial factor stimulated by carbon dioxide (Hamel, 2004; Lavi, Egbarya, Lavi, & Jacob, 2003) affecting vascular tone. Although these effects are known for parenchymal vascular beds, the direct effect of NO on the basal cerebral arteries, and their upstream subcranial arteries (i.e. vertebral arteries and internal carotid arteries), remains unknown, particularly in humans.
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New Findings
• What is the central question of this study?
Nitric oxide causes dilatation in peripheral vessels;
however, whether nitric oxide affects basal cerebral artery dilatation has not been explored.
• What is the main finding and its importance?
This study demonstrated that vasodilatation occurs in the right middle cerebral artery in response to exogenous nitric oxide. However, blood velocity decreased and, therefore, overall cerebral blood flow remained unchanged. This study provides new insight into the role of nitric oxide in cerebral blood flow control.
Drugs such as sodium nitroglycerin (NTG) deliver an exogenous source of NO to large coronary and peripheral conduit vessels, where they cause dilatation (Arnold, Mittal, Katsuki, & Murad, 1977; Ignarro, Ross, & Tillisch, 1991; Parratt, 1979) . When administered sublingually, this lipid-soluble drug is rapidly absorbed over the mucosal membranes in the mouth (Zhang, Zhang, & Streisand, 2002) . Sodium nitroglycerin has a half-life of ∼2.5 min (Kirsten, Nelson, Kirsten, & Heintz, 1998b) and acts as a metabolism-dependent NO donor, amplifying NO production and eliciting subsequent vasodilatory effect(s) (Kirsten et al., 1998b; Kirsten, Nelson, Kirsten, & Heintz, 1998a) . Therefore, NTG is viewed as an ideal drug both for clinical use and for studying non-endothelial vasomotor function (Mao et al., 2012) . In addition, NTG can cross the blood-brain barrier and act directly on the vascular smooth muscle cells (independent of the endothelium), where it is assumed to biotransform to NO (Chen, Zhang, & Stamler, 2002) . Based on observations in the brachial artery vascular bed, exogenous NO dilates conduit arteries some distance from the heart, but with little change in total blood flow and systemic blood pressure, owing to concurrent vasoconstriction (preventing dilatation) in the downstream vascular bed (Anderson, Meredith, Ganz, Selwyn, & Yeung, 1994; Ignarro et al., 1991) . Consequently, NTG may provide a useful tool to study NO-mediated control of large cerebral arteries. Despite its popular use in patients with cardiovascular disease, the role of NTG (and, therefore, NO) in the cerebrovasculature remains unstudied.
Therefore, this study tested the hypothesis that NO causes vasodilatation in the MCA of the circle of Willis. Additional focus on its blood flow provided insight into both the conduit vessel and the downstream vascular bed in response to exogenous NO.
METHODS

Ethical approval
Each participant was required to provide informed written consent to the protocols, which were approved by the Western University Health Sciences Research Ethics Board (HSREB: 107620). This study conformed to the standards set by the Declaration of Helsinki except for registration in a database.
Participants
Ten young, healthy individuals participated in this study (eight females, unknown menstrual phase; Table 1 ). Participants expressed no history of medication, cardiovascular disease or neurological disorder.
Participants refrained from alcohol, caffeine and exercise for 12 h before testing.
Experimental protocol
Data were collected during two testing sessions that were performed on separate days: (i) a laboratory session; and (ii) a MRI session. In each session, measurements were made before and after NTG treatment (0.4 mg, Nitrolingual Pumpspray; Sanofi, Laval, QC, Canada) and separately during a placebo (PLO), composed of water and peppermint oil to match the flavour of NTG. Each treatment was provided via sublingual spray. All participants were blinded to treatment, and treatments were administered in a random order in the laboratory session that was then repeated in the MRI session.
Laboratory session measurements
Height, weight and age were acquired from each participant ( 
TA B L E 1 Participant characteristics
Males/females (n) 10, 2/8
Body mass index (kg m −2 ) 21 ± 2 Systolic blood pressure (mmHg) 117 ± 13
Diastolic blood pressure (mmHg) 66 ± 7
Values are means ± SD.
MRI session measurements
All cerebrovascular anatomy measurements were performed on a 7 T neuro-optimized MRI scanner (Siemens MAGNETOM; Erlangen, Germany) using an in-house-built eight-channel transmit, 32-channel head coil. Cross-sectional area (CSA) measurements were made of the rMCA using a T1-weighted 3D SPACE pulse sequence (Park, Mugler, Horger, & Kiefer, 2007 ) using a sagittal orientation, at high resolution (0.5 mm isotropic, whole brain), with the following imaging parameters: TE = 8.2 ms, TR = 700 ms, FOV = 224 mm, matrix = 448 × 448 × 256, turbo factor = 96, BW = 587 Hz/px, iPat = 2 and TA = 5:38 min. A radial trajectory minimized the echo time, as it is robust to motion and the distribution of artefacts (Glover & Pauly, 1992) . First, a baseline T1 image (requiring 5-6 min to complete) was captured. Thereafter, a second and third T1 image were captured, commencing at 2 min after NTG or PLO administration to capture the period of peak dilatation. Of note, our laboratory demonstrated that MCA dilatation in response to hypercapnia develops progressively, with the peak response occurring at 3-4 min (Coverdale et al., 2015) . Additionally, peak brachial dilatation in response to NTG occurs ∼3 min postspray (Ducharme, Dupuis, McNicoll, Harel, & Tardif, 1999) . Therefore, we anticipate that our imaging parameters capture a time period of maximal NTG effect.
Thereafter, a time-of-flight (TOF) image was captured for structural/topological layout of the brain's conduit artery angiogram ( Figure 1 ). As in the laboratory session, 20 min of recovery provided after each treatment allowed values to return to baseline. The P ET,CO 2 levels were monitored continuously via a modified oxygen mask (Trudell Medical Marketing Ltd, London, ON, Canada) with a built-in sampling port, and a sampling line connected to a gas analyser (Biopac MP150; Biopac Systems Inc., Montreal, QC, Canada). All MRI images were saved as DICOM files for offline analysis.
Data analyses
Laboratory measurements of CO, SV, HR, mean arterial pressure Stroke volume (ml) 79 ± 32 76 ± 32 79 ± 28
Laboratory P ET,CO 2 (mmHg) 42 ± 4 4 2± 4 4 1± 5 MRI P ET,CO 2 (mmHg) 45 ± 6 45 ± 7 45 ± 7
Heart rate (beats min −1 ) 6 2± 10 64 ± 11 66 ± 10* MAP (mmHg) 83 ± 12 86 ± 14 86 ± 13 rMCA V (cm s −1 ) 6 7 ± 10 62 ± 10 ‡ 59 ± 9.3* rMCA CSA (mm 2 ) 5.2 ± 1.2 5.4 ± 1.5 6.6 ± 1.5* † rMCA F (ml min −1 ) 221 ± 37.4 218 ± 35.0 213 ± 46.4 rMCA C (ml min mmHg −1 ) 2.7 ± 0.5 2.6 ± 0.8 2.6 ± 0.6
Brachial V (cm s −1 ) 3 . 0 ± 1.6 2.6 ± 1.9 2.8 ± 2.2
Brachial CSA (mm 2 ) 7.5 ± 2.2 7.8 ± 2.3 9.0 ± 2.2* † Brachial F (ml min −1 ) 1 4± 11 13 ± 12 16 ± 16
Values are means ± SD. Abbreviations: C, conductance; CSA, crosssectional area; F, flow; MAP, mean arterial pressure; P ET,CO 2 , partial pressure of end-tidal carbon dioxide; rMCA, right middle cerebral artery; and V, velocity. * NTG different from BL (P < 0.05). † NTG different from PLO (P < 0.05). ‡ PLO different from BL (P < 0.05).
During the MRI, P ET,CO 2 was monitored to ensure stability, and averaged over 30 s obtained 2.5 min into the T1 scan ( Table 2) 
Statistical analysis
The effect of treatment on the rMCA CSA and haemodynamic outcomes was assessed using a one-way repeated-measures ANOVA, with a Bonferroni correction for multiple comparisons. The effects of treatment and time (each minute value) on MCA and brachial artery blood velocity data, normalized to baseline values, were assessed using a two-way repeated-measures ANOVA with a Bonferroni correction.
A Bland-Altman test compared the blinded analyses of rMCA CSA from the two observers. The probability level for statistical significance was 0.05. Statistical analyses were performed in SPSS (SPSS 23; IBM Corporation, Armonk, NY, USA), and all data are presented as the mean ± SD.
RESULTS
Cross-sectional area
All data passed a Sharipo-Wilk test of normality. Brachial artery CSA increased [F(2,18) = 13.92, P < 0.001] with NTG compared with both BL (9.0 ± 2.2 versus 7.5 ± 2.2 mm 2 , respectively, P < 0.01) and PLO (7.7 ± 2.3 mm 2 , P < 0.05), whereas measurements for BL and PLO treatments were similar (Figure 3a) . The rMCA behaved in a similar manner [F(2,18) = 14.13, P < 0.001], in that CSA increased during NTG administration (6.6 ± 1.5 mm 2 ) compared with both BL (5.2 ± 1.2 mm 2 , P < 0.001) and PLO (5.4 ± 1.5 mm 2 , P < 0.05);
however, BL and PLO values were similar (Figure 3b ). The BlandAltman analysis of rMCA CSA between observers showed an interrater bias of 0.6604 ± 1.075 mm 2 (95% confidence interval 1.45-2.77) but no proportional bias. Post hoc power analysis (G*Power; HeinrichHeine-Universität, Düsseldorf, Germany) for rMCA measurements was 0.99.
Blood velocity
Brachial artery velocity values did not change over time in either the NTG or PLO conditions (Figure 4a ). However, a significant treatment × time interaction [F(2,18) = 87.21, P < 0.0001) indicated that MCA blood velocity during NTG was lower than during PLO at each time point after the first minute (Figure 4b ; P < 0.05).
Other haemodynamic measurements
No effect of treatment was observed for MAP or P ET,CO 2 (Table 2) .
Heart rate increased [F(2,18) = 5.89, P < 0.05] during NTG compared with BL (66 ± 10 versus 62 ± 10 beats min −1 , respectively, P < 0.05).
Calculated total flow and vascular conductance in both brachial and rMCA vessels were similar to BL during NTG and PLO administration (Table 2) .
DISCUSSION
The major findings of this study are as follows: (i) the rMCA dilated in response to NTG administration; and (ii) despite an increase in CSA, there were no changes in overall flow, in both the MCA and brachial artery vascular beds. Therefore, exogenous NO dilates the large conduit basal cerebral arteries, but not the downstream vascular beds, in both brachial and rMCA vascular beds.
Sodium nitroglycerin is a common drug used to treat angina pectoris through its effect on dilatation of both large arteries and veins (Parratt, 1979) . This, in turn, reduces both cardiac afterload and preload, respectively (Ludbrook, Byrne, Kurnik, & McKnight, 1977) , with little change in blood pressure (Gori, Floras, & Parker, 2002; Nyberg & Westling, 1981) . These changes appear to be mediated by concurrent increases in HR, and a blunting of baroreflex sensitivity facilitates increasing sympathetic contributions to cardiovascular control (Gisolf et al., 2004; Gori et al., 2002) .
In this study, the expected brachial artery vasodilatation occurred during NTG (Anderson et al., 1994; Ignarro et al., 1991) . A similar dilatory effect of ∼24% was observed in the rMCA perfusing the brain. Unexpectedly, the PLO also caused a small dilatory response, accounting for ∼4% of the change of CSA. Possible explanations for the PLO-induced dilatation include a genuine placebo effect, or random sampling error and/or variability owing to the small sample size. Another explanation might be that the peppermint oil that forms a component of the NTG treatment was added to water in this study to produce a similar taste between the PLO and NTG treatments. Sodium nitroglycerin includes 1% menthol because it potentiates dilatory effects (Busiashvili, 2003) . Peppermint oil contains menthol, an agonist for transient receptor potential melastatin 8 (TRPM8; Johnson et al., 2009 ). This receptor elicits dilatation in large arteries, such as the aorta (Johnson et al., 2009) . Menthol also attenuates vasoconstriction in the mesenteric arteries (Sun et al., 2014) . We speculate that these actions might also occur in the cerebral vessels. Regardless, the small (∼4 ± 19%) dilatation with PLO does not account for the much larger (∼28 ± 15%) MCA dilatation after NTG, leaving ∼24% attributed to exogenous NO. Additionally, we subtracted the CSA of PLO from NTG, and added that value to the BL values to determine the effect of exogenous NO. Using Student's two-tailed paired t test, P < 0.05, indicating that exogenous NO significantly increases CSA.
The observation that exogenous NO causes cerebral artery dilatation is novel in humans although these data are preceded by earlier studies in rodents, in which exogenous NTG caused vasodilatation in the large intracranial arteries (Kistler, Vielma, & Davis, 1982) . Furthermore, single photon emission computed tomography measurements of CBF and TCD measurements of MCA blood velocity (to estimate changes in diameter) indicated an increase in calculated MCA diameter after NTG administration (Dahl, Russell, NybergHansen, & Rootwelt, 1989) . The present study confirms these earlier studies, with the first direct measurements of the MCA during NTG administration in healthy adults. The values of P ET,CO 2 before and during NTG were similar in both the MRI and the laboratory, indicating that the MCA response to NTG occurred independently of any confounding sources of dilatation elicited by hypercapnia. Of note, the changes in rMCA CSA observed in the present study (5.2-6.6 mm 2 ) after NTG are similar to those provided earlier in response to hypercapnia in different individuals (5.6-6.5 mm 2 ; Coverdale, Gati, Opalevych, Perrotta, & Shoemaker, 2014) .
This study indicates an important role for exogenous delivery of NO in cerebral conduit vessel control. However, the role of endogenous NO in conduit vessel dilatation remains equivocal. In rats, pharmacological blockade of NO synthase (NOS) attenuated the increase in CBF during hypercapnia, demonstrating the role of NO in cerebrovascular dilatation (Wang, Paulson, & Lassen, 1992) . In contrast, human studies of CBF control using NOS inhibition have produced conflicting results; some studies reported little effect of NOS on total CBF during reactive hypercapnic states (Ide, Worthley, Anderson, & Poulin, 2007) , whereas others reported a blunted increase in MCA blood velocity with hypercapnia after NOS inhibition (Schmetterer et al., 1997) . A major difference between these earlier studies in humans is that the former measured total flow, whereas the latter measured blood velocity, not accounting for conduit artery CSA. Previously, researchers in our laboratory (Coverdale et al., 2014) and others (Verbree et al., 2014) demonstrated with high-field MRI that measurement of blood velocity underestimates the changes in CBF during hypercapnia and hypocapnia. Therefore, the discrepancy regarding the effect of NO on CBF control can be resolved with conduit artery CSA measurements. In this perspective, the combined data suggest that NO has a specific role in dilating basal cerebral and subcranial arteries.
Measurements of both MCA CSA and flow velocity provide insight into the effect of NTG on both the conduit artery and the downstream vascular bed. Thus, a second major outcome of this study was the observation that, despite the increase in CSA after NTG and stable MAP, blood velocity decreased in the MCA such that overall CBF remained unchanged. This observation supports previous findings of reductions in MCA blood velocity after sublingual NTG administration (Dahl et al., 1989; Zuj et al., 2012) . Likewise, others observed diminished MCA blood velocity but little change in regional CBF after intravenous infusions of sodium nitroglycerin (Iversen, Holm, Friberg, & Tfelt-Hansen, 2008; White et al., 2000) . Despite known sensitivity of parenchymal vessels to NO (Anderson et al., 1994; Ignarro et al., 1991; Lavi et al., 2003) , the observation of similar vasomotor responses in the vascular beds of the MCA and brachial arteries suggests a similar underlying physiology. One possible mechanism could be a sympathetic nervous system response that has proportionately greater effects in the downstream versus conduit vessels, thereby competing with the dilatory effect of the delivered NO. Previously, it has been reported that NTG leads to a reflexive increase in plasma noradrenaline to counter the druginduced hypotension (Tassorelli, Blandini, Costa, Preza, & Nappi, 2002) .
Other in vivo studies in the rat and guinea-pig determined that intravenous NTG administration induced increases in noradrenaline, mimicking biological responses associated with sympathetic neuronal activity in perfused atria and cerebrospinal fluid (Ma & Long, 1991a, b, c; Ma, Schmid, & Long, 1994; Tassorelli et al., 2002) . In humans, chronic NTG administration decreased baroreflex sensitivity and increased sympathetic neural modulation of heart rate (Gori et al., 2002) . Furthermore, acute reflexive sympathetic vasoconstriction in the cerebral circulation has been difficult to observe in the human brain in conditions of stable blood pressure (Sándor, 1999) , although small effects have been observed using a lower-body negative pressure suction model (Wilson, Serrador, & Shoemaker, 2003) . Thus, although the literature remains uncertain of the magnitude of sympathetic activation in the control of CBF (Brassard, Tymko, & Ainslie, 2016) , neurogenic vasoconstriction might be one potential compensatory mechanism to counter the drug-induced dilatation.
Limitations of this study include the collection of MRI and laboratory measurements on different days owing to MRI availability.
However, existing data suggest that this effect might be negligible.
For example, TCD estimates of flow velocity are reproducible for up to 1 week (Demolis, Chalon, & Giudicelli, 1993) , and phase-contrast MRI analyses for estimating CBF are reproducible over 72 days (Spilt et al., 2002) . Furthermore, a single-subject study demonstrated that over 20 consecutive days, measurement of velocity in the MCA using TCD is reliable (Vingerhoets & Stroobant, 2002) . and 50 mmHg, the increase in velocity remains relatively linear. We
do not yet know the CSA-P ET,CO 2 dose-response relationship, but the values we obtained occurred on the linear part of the velocity-P ET,CO 2 curve; therefore, we can infer that the difference between the two testing sessions may be small. To address this possibility, we evaluated changes in CSA, although this may not directly address the problem of baseline CSA affecting the responsiveness of the MCA to exogenous NO.
A third possible limitation is the time between treatment administrations and the lack of a second baseline measurement before the second treatment. As mentioned, the half-life of NTG in plasma is ∼2.5 min (Kirsten et al., 1998b) . Seven half-lives were allowed after the NTG treatment to optimize the loss of drug effects. Furthermore, haemodynamics, velocity levels in the MCA and brachial artery, and the vessel diameters indicated reinstitution of baseline conditions between PLO and NTG conditions. Also, the order of treatments was randomized to ameliorate the potential problem of treatment carryover effects. Maximal vasodilatation in the brachial artery is observed 2 min post-NTG administration (Ducharme et al., 1999) , becoming barely detectable after 20 min (Armstrong, Armstrong, & Marks, 1979) . Therefore, physiological measures suggested that a return to baseline conditions had occurred after 20 min, although some residual but undetectable NTG effects might have persisted in some individuals in whom NTG was given before PLO.
Conclusion
The rMCA dilated in response to sublingual 0.4 mg NTG, suggesting an NO-mediated mechanism. This dilatation did not change total flow because of concurrent reductions in blood velocity, suggesting differential drug effects on conduit arteries versus microvascular territories.
